GlassScriptPhysician profile
Leroy Jones
NPI 1518947613
$505,931.87
in general payments reported to CMS, 2019-2025
31 companies · $51K in 2025
The $51K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $42K · 2021: $45K · 2022: $82K · 2023: $86K · 2024: $73K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Consulting Fee: $57K · Travel and Lodging: $15K · Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $123,900.00 |
| Consulting Fee | $57,232.50 |
| Travel and Lodging | $15,041.49 |
| Food and Beverage | $13,479.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $462,537.89 | 2019-2025 | Advance Xp, General - Erectile Dysfunction, Ams 800 Artificial Urinary Sphincter |
| Coloplast Corp | $28,618.97 | 2019-2025 | Titan |
| Acerus Pharmaceuticals Corporation | $5,805.65 | 2022-2023 | Natesto |
| Edap Technomed INC | $3,594.00 | 2024 | |
| Axonics, INC. | $1,607.85 | 2021-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $1,139.36 | 2023 | Interstim |
| Endo Pharmaceuticals INC. | $405.02 | 2019-2024 | Xiaflex |
| Antares Pharma, INC. | $330.24 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Janssen Biotech, INC. | $320.86 | 2019-2024 | Erleada, Akeega, Balversa |
| Sn Holdings, LLC | $178.00 | 2021 | |
| Endo USA, INC. | $146.32 | 2024-2025 | Xiaflex |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
| Astellas Pharma US INC | $123.07 | 2019-2024 | Xtandi |
| Teleflex LLC | $116.84 | 2022-2024 | Urolift |
| Innovation Technologies INC | $106.53 | 2021-2024 | Irrisept |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $102.65 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $82.43 | 2023-2024 | Gemtesa |
| Calyxo, INC. | $78.26 | 2025 | Cvac Aspiration System |
| Abbvie INC. | $74.68 | 2024 | |
| Urogen Pharma, INC. | $63.96 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $59.57 | 2024-2025 | Lynparza, Keytruda |
| Olympus America INC. | $53.90 | 2025 | Itind System |
| Urovant Sciences INC | $49.76 | 2022 | |
| Halozyme INC | $46.43 | 2023 | |
| Tolmar, INC. | $45.42 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.61 | 2024 | |
| Procept Biorobotics Corporation | $24.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.73 | 2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $22.62 | 2024 | Provenge |
| Progenics Pharmaceuticals, INC. | $22.61 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.